• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Events

ASTMH 2014

2-6 November 2014

New Orleans, United States

Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

 

DNDi presented a symposium on human African trypanosomiasis (sleeping sickness), presented new results from an ASMQ clinical study in children, participated in a symposium on Kinetoplastid diseases, and made oral and poster presentations.

DNDi also co-sponsored a side event on Chagas disease.

  • DNDi @ ASTMH

Symposium

DNDi Symposium: #164
Towards the elimination of human African trypanosomiasis (HAT)

Date: November 5, 2014
Chair: Jose Ramon Franco, WHO
Co-chair: Crispin Lumbala, PNLTHA

Veerle Lejon, IRD
Advances and challenges in current diagnostics for HAT
Antoine Tarral, Head of HAT Clinical Program, DNDi
New oral treatments for HAT
Wilfried Mutombo, Coordinating investigator, Fexinidazole study for HAT, PNLTHA
Implementation of studies in remote areas in countries with limited regulatory and ethics experience
Jose Ramon Franco Minguell, Department of Control of Neglected Tropical Diseases, WHO
How to achieve HAT elimination with current and new tools

 

MSF Symposium: #153
Transitioning from Vertical to Horizontal: Challenges In Integrating Diagnosis and Treatment of Kinetoplastid Diseases in Essential Health Services

Date: November 5, 2014
Chair: K. Ritmeijer, MSF Holland
Co-chair: François Chappuis, HUG, Geneva

Maria Angeles, MSF, Spain
The right balance between vertical and horizontal approaches to diagnose and treat kinetoplastid diseases: the MSF experience
Crispin Lumbala, Ministry of Health, Kinshasa, DRC
Integration of HAT control into primary healthcare and HAT elimination: achievements and challenges in the DRC
François Chappuis, HUG, Geneva
From a disease-specific to a syndromic diagnostic approach: the cases of visceral leishmaniasis and human African trypanosomiasis
Nathalie Strub-Wourgaft, Medical Director, DNDi
New kinetoplastid diseases treatment that can be easily delivered in rural health posts: when will they be available?
Oral Presentation

Efficacy, Safety and Population Pharmacokinetics of the Artesunate Mefloquine (ASMQ) Fixed Dose Combination versus Artemether Lumefantrine for the Treatment of Uncomplicated Falciparum Malaria in African children

Download Presentation

Date: November 4, 2014
Scientific Session 64: Malaria: Drug Development – New Approaches, Efficacy, Safety and Pharmacology

Sodiomon Sirima1, Bernhards Ogutu2, John Lusingu3, Ali Mtoro4, Zakayo Mrango5, Alphonse Ouedraogo1, Jean Baptiste Yaro1, Kevin Omondi Onyango6, Samwel Gesase3, Ernest Mnkande4, James Samwel Ngocho5, Joelle Vanraes7, Nathalie Strub7, Gwenaelle Carn7

1.) Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso
2.) The Kenya Medical Research Institute, Kisumu, Kenya
3.) National Institute for Medical Research, Korogwe, United Republic of Tanzania
4.) Ifakara Health Institute, Bagamayo, United Republic of Tanzania
5.) National Institute for Medical Research, Kilosa, United Republic of Tanzania
6.) The Centre for Clinical Research- Kenya Medical Research Institute, Nairobi, Kenya
7.) Drugs for Neglected Diseases initiative, Geneva, Switzerland

Drug discovery and development for the treatment and control of filariasis: repurposing emodepside

Download Presentation

Date: November 4, 2014
Scientific Session 108: Filariasis: Clinical
Sabine Specht 1, Charles MacKenzie1, Coralie Martin1, Simon Townson1, Robert Don2, Achim Hoerauf1, Ivan Scandale2

1.) Institute for Medical Microbiology, Immunology & Parasitology, University Hospital Bonn, Sigmund Freud Str. 25, 53127 Bonn, Germany
2.) Drugs for Neglected Diseases initiative, Geneva, Switzerland

 

Poster Presentations



The AMFm in Ghana: Factors Associated with Private Retailers: Adherence to the Recommended Retail Price

Download Poster

Date: November 5, 2014
Poster session C
John H. Amuasi*1, Beth Virnig1, Graciela Diap2, The AMFm Independent Evaluation Team3

1.) University of Minnesota School of Public Health, Minneapolis, MN, United States
2.) Drugs for Neglected Diseases initiative, Geneva, Switzerland
3.) Komfo Anokye Teaching Hospital, London School of Hygiene and Tropical Medicine, ICF International, Kumasi, Ghana; London, United Kingdom; Rockville, MD, United States

Oral flubendazole: a potentially useful macrofilaricide
Flubendazole, a potential useful chemotherapeutic agent for treatment and control of filarial infections

Download Poster

Date: 
November 3, 2014
Poster session A

Charles D. Mackenzie1, Timothy G. Geary2, Sabine Specht3, Maeghan O’Neill2, Kennan Marsh4, Achim Hoerauf3, Ivan Scandale5, Steven Silber6

1.) Michigan State University, East Lansing, MI, United States
2.) McGill University, Quebec, QC, Canada
3.) Medical University, Bonn, Germany
4.) AbbVie, North Chicago, IL, United States
5.) Drugs for Neglected Diseases initiative, Geneva, Switzerland
6.) JRD, Raritan, NJ, United States

Chagas Side Event

Changing the Face of Chagas Disease: Scaling Up Diagnosis, Treatment and R&D for People Living with Chagas Disease in the Americas
November 3, 2014

  • Download Save the Date
  • More information

More information: ASTMH website

Side Event

Changing the Face of Chagas Disease:
Scaling Up Diagnosis, Treatment and R&D for People Living with Chagas Disease in the Americas

Chagas Event ASTMH 2014

On November 3, 2014 the Chagas Coalition presented a panel discussion and reception on radically scaling up diagnosis, treatment and research and development (R&D) for people living with Chagas disease, the leading parasitic killer of the Americas.

Coinciding with the American Society of Tropical Medicine and Hygiene (ASTMH) 63rd Annual Meeting taking place in New Orleans, Louisiana, this complementary side event on November 3 was hosted by the Tulane University School of Public Health and Tropical Medicine and brought together patients, researchers, clinicians, and policymakers to shed light on the treatment and research needs of people living with Chagas disease.

Speakers included:

  • Dr Pierre Buekens, Tulane University School of Public Health and Tropical Medicine
  • Dr Peter Hotez, Sabin Vaccine Institute/National School of Tropical Medicine at Baylor College of Medicine; Past President, ASTMH
  • Dr Isabela Ribeiro, DNDi
  • Dr Nines Lima, Médecins Sans Frontières
  • Dr Sheba Meymandi, Olive View Medical Center
  • Dr Anthony Fiore, Centers for Disease Control and Prevention
  • Dr Luis Gerardo Castellanos, Pan American Health Organization
  • Maira Gutierrez, Chagas disease patient representative
  • Watch video of the event
  • Listen to Maira Gutierrez, Chagas disease patient representative
  • Download Event Invitation

This event was co-organized by:

Press Releases

[New Orleans, LA, USA  – 4 November, 2014]
Artesunate-Mefloquine Fixed-Dose Combination (ASMQ FDC) Proves Safe and Efficacious to Treat Children in Africa with Malaria
Clinical Trial Results Provide Evidence for Introducing This Artemisinin Derivative-based Combination Therapy (ACT) into Africa’s Current Malaria Treatment Arsenal to Help Tackle the Number One Parasitic Killer 
Presented today at the 63rd annual meeting of the American Society of Tropical Medicine and Hygiene (ASMTH), results of a multi-centre clinical trial in Africa, launched in 2008, to test the efficacy and tolerability of ASMQ fixed-dose combination (FDC) in children under 5 years of age with uncomplicated falciparum malaria showed that ASMQ FDC is as safe and efficacious as Artemether-Lumefantrine (AL) FDC – Africa’s most widely adopted treatment.
[Français]

More

[New Orleans, LA, USA  – 2 November, 2014]
DNDi Receives USD 60 Million to Fill Research and Development Gaps for Neglected Patients
The Drugs for Neglected Diseases initiative (DNDi) has been awarded USD 60 million by the Bill and Melinda Gates Foundation towards the development of new and effective treatments for patients suffering from neglected tropical diseases in the world’s poorest communities. Announced today by Mr Bill Gates at the annual meeting of the American Society of Tropical Medicine and Hygiene (ASTMH) in New Orleans, this grant will help fill critical gaps in research and development (R&D) for human African trypanosomiasis (sleeping sickness), filarial diseases (notably onchocerciasis, or river blindness), and visceral leishmaniasis (kala-azar).

More

Other events

Loading...
8-12 May 2023

Lisbon, Portugal and online

ESPID 2023

13 April 2023, 2 PM London

London, United Kingdom

Ending the neglect of Chagas disease in the UK

11-12 April 2023

Barcelona, Spain and online

XVIII Jornadas sobre la enfermedad de Chagas

27-31 March 2023

Online

Global meeting on skin-related neglected tropical diseases

See all

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo